16 November2026: IDEAYA reports FDA alignment on IDE849 phase 2/3 registrational trial designs in neuroendocrine carcinomas
IDEAYA Biosciences announced successful US FDA type C meeting discussions on the registrational development strategy for IDE849, an investigational DLL3-targeted TOP1 inhibitor ADC, in previously treated 2L+ neuroendocrine carcinomas(NEC). the company plans to initiate a single-arm phase 1/2 extension cohort and a randomized phase III registrational trial by the end of 2026 to pursue potential accelerated and full FDA approval
The registrational strategy is supported by updated Phase I data presented by partner Hengrui at ESMO 2026. Among 19 patients with NEC treated at doses of ≥1.8 mg/kg IV every three weeks, IDE849 demonstrated confirmed ORR of 36.8%, DCR of 84.2%, median PFS of 7.0 months and a 9-month OS rate of 82.4%
IDE849 addresses an important unmet need in previously treated NEC patients, including gastroenteropancreaticNEC and large-cell NEC, where treatment options are limited following first-line platinum-based chemotherapy. DLL3 expression across multiple NEC subtypes provides a rationale for expanding the therapy beyond small-cell lung cancer
IDE849 is a DLL3-targeted ADCcomprising a humanized anti-DLL3 IgG1 antibody linked to a potent topoisomerase I inhibitor payload through a cleavable linker. It selectively delivers the cytotoxic payload to DLL3-expressing tumour cells, resulting in DNA damage and tumour-cell death
IDEAYA plans a ~90-patient single-arm GEP-NEC cohort to support potential accelerated approval, a randomized phase III trial across GEP-NEC and LC-NEC for full approval, and a separate phase III trial of IDE849 in Imdelltra-pretreated ES-SCLC. IDEAYA holds global rights outside Greater China through its Hengrui licensing agreement